Osteoarthritis year 2012 in review: genetics and genomics  by van Meurs, J.B.J. & Uitterlinden, A.G.
Osteoarthritis and Cartilage 20 (2012) 1470e1476Review
Osteoarthritis year 2012 in review: genetics and genomics
J.B.J. van Meurs yz*, A.G. Uitterlinden yzx
yDepartment of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
z The Netherlands Genomics Initiative-sponsored Netherlands Consortium for Healthy Aging (NGI-NCHA), Leiden/Rotterdam, The Netherlands
xDepartment of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlandsa r t i c l e i n f o
Article history:
Received 7 June 2012
Accepted 8 August 2012
Keywords:
Genetics
Genomics
DNA-variants
Osteoarthritis* Address correspondence and reprint requests t
Laboratory, Department of Internal Medicine, Room E
2040, 3000 CA, Rotterdam, The Netherlands. Tel: 31-
E-mail address: j.vanmeurs@erasmusmc.nl (J.B.J. v
1063-4584/$ e see front matter  2012 Osteoarthriti
http://dx.doi.org/10.1016/j.joca.2012.08.007s u m m a r y
The ﬁeld of genetics and genomics is a highly technological driven ﬁeld that is advancing fast. The
purpose of this year in review of genetics and genomics was to highlight the publications that apply
these new technologies tools to improve understanding of the pathophysiology of osteoarthritis (OA). In
addition, most recent developments in genetics and genomics research and their relevance to OA are
discussed in this review.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Failure to understand the pathophysiology of osteoarthritis (OA)
frustrates efforts to improve therapeutic strategies. Genome-wide
genetic and genomic approaches have the potential to ﬁnd novel
biological pathways involved in OA, since these methods are
hypothesis-free and do not suffer from the bias of previous
knowledge. The discovery of novel genes might help to understand
the development of OA and has the potential to identify novel
treatment options. In addition, more personalized medicine
options for OA can be explored through prediction of risk for
disease as well as classiﬁcation in disease subtypes.
Over the last year, substantial advances have been made in
genetics and genomics of OA as evidenced by results from the
TREAT-OA and arcOGEN consortia. Powerful genome-wide associ-
ation studies (GWAS) have been performed and new genomics
technology have been applied to the ﬁeld over the last year, which
are now beginning to bear fruit. This review is a summary of
studies, selected by the author, related to genetics and genomics
published between May 2011 and May 2012 and on data presented
during the OA Research Society International (OARSI) 2012, which
was held from April 26e29 2012 in Barcelona, Spain. In addition,
most recent developments in genetics and genomics research and
their relevance to OA will be discussed.
Genetic research is done (1) to identify underlying causative
genes and pathways, and thereby understand more about theo: J.B.J. van Meurs, Genetic
e579b, Erasmus MC, PO Box
107038425.
an Meurs).
s Research Society International. Pbiology of the disease with potential implications for development
of novel treatments, and (2) to be able to predict risk of disease by
genotyping the identiﬁed risk alleles. So far, most research is
focused on identifying novel OA genes to understand more of the
disease biology, resulting in the identiﬁcation of common genetic
variants with modest effect size.
Genetic architecture of OA
Through twin studies it has been well-established that OA and
its endophenotypes, are to a large extent genetically determined,
but the underlying genetic variants are mostly unknown. In terms
of how many, what type, and which genetic variants explain the
genetic variance of OA, i.e., the genetic architecture, we can
distinguish several possibilities. The genetic architecture of OA is
similar to other complex diseases with contributions of several and
perhaps hundreds of genes, with most having small effects and
a few having large effects (Fig. 1). Among these we can distinguish
early onset OA, which usually represents a monogenic Mendelian
disease type that can be mapped by linkage analysis in families, or
nowadays by exome sequencing of affected subjects. On the other
hand we can recognize late onset OA, which represents the
common form of OAwith a usual age at onset of >60 years, and for
which genetic association approaches have been shown to be
fruitful in identifying underlying genetic factors.
Early onset OA
The early onset syndromic OA has an obvious genetic defect and
high penetrance in a low number of families. These syndromesublished by Elsevier Ltd. All rights reserved.
Fig. 1. Genetic architecture of susceptibility to OA. Genetic loci that are known to be
associated to risk for OA comprise rare variants of large effect3,4,10,11,40e42 and common
variants of small effect6,7,19,24,29,43e46. Common variants of large effect have not been
identiﬁed and probably do not exist. It is likely that uncommon variants of moderately
large effect exist and contribute to risk for OA. These will most likely be found using
next generation technology in families and population data.
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disproportionate short stature and skeletal malformations. These
genetic skeletal disorders are caused by disturbances in the
complex process of skeletal development at many stages and can
vary a lot in their appearance and severity (see Ref. 1 for overview).
These disorders are caused by mutations in genes encoding for
proteins involved in various functions, i.e., extracellular matrix
proteins and growth factors involved in cartilage/bone develop-
ment, but also other less understood pathways such as post-
translational processing and transport2. These “experiments of
nature” can give us important insight into disease processes. Over
the last year, several interesting newgeneswere identiﬁed to be the
cause of early onset OA. First, mutations in SMAD3 (SMAD family
member 3) were identiﬁed as the cause of aneurysm-OA syndrome
(AOS)3. This study showed the existence of coupling between
aneurysms and OA via the TGF (Transforming Growth Factor) beta
signaling pathway. A second gene identiﬁed to be involved in OA
through family research is the TRPV4 (transient receptor potential
cation channel, subfamily V, member 4) gene4. Mutations that reduce
channel activity were shown to cause inherited osteoarthropathy,
which indicates a role for TRPV4 activity in articular cartilage
homeostasis. Another interesting family was published in the
journal Nature Genetics last year, where deletion of MIR17HG,
encoding the miR-17w92 polycistronic miRNA cluster on chro-
mosome 13, resulted in a clear skeletal phenotype (microcephaly,
short stature and digital abnormalities)5. These ﬁndings identiﬁed
a regulatory function for miR-17w92 in growth and skeletal
development and represent the ﬁrst example of a miRNA gene
responsible for a syndromic developmental defect in humans.
Interestingly, some of the genes found for the monogenic syn-
dromic form of OA, have also been implicated to play a role in
normal, late onset OA (also shown in Fig. 1). For example the GDF5
(growth differentiation factor 5) and SMAD3 genes, for which it was
shown that common polymorphisms in these genes are associated
with knee and hip OA6,7.
Late onset OA
There have been several attempts to ﬁnd OA genes via similar
approaches in families where the common form of OA is segre-
gating using the so-called linkage approach8. However, mostlinkage studies have been unsuccessful in identifying genes
involved in OA, and so a switch to the genetic association study
design has been made in OA research, similar to other common
complex diseases. Until the technical possibility of examining the
complete common genomic variation of the genome by GWAS
technology became available, researchers had to choose their
candidate genes based on prior knowledge. Since knowledge of the
etiology of OA is poor and, in general, power of the single cohorts is
low, these studies have yielded inconsistent results (extensively
reviewed in Ref. 9).
There is one well replicated risk gene which reaches the
genome-wide signiﬁcance level (p < 5 108) that originated from
such a candidate gene study: the GDF5 gene. Rare inherited skeletal
dysplasias such as Chondrodysplasia grebe type and brachydactyly
type C are caused by mutations in GDF10,11. Common functional
variation in this gene, affecting transcription of this gene, was
recently shown to be involved in late onset OA12 in both Asians as
well as Europeans13,14.
The GWAS era
GWAS have been successfully applied to the study of many
complex diseases and in less than 5 years have identiﬁedmore than
1,500 loci that predispose to diseases and quantitative traits (see
www.genome.gov/gwastudies). Several GWAS studies for OA have
been published over the last year9. It is evident that the number
of published loci that were found robustly associated with OA up
to the start of 2012 was low. The reason for this is e as we now
know emost likely lack of power. Power in a genetic epidemiology
study is dependent of sample size and phenotype heterogeneity.
Sample size
The studies that had been published up to the start of 2012 all
had low to moderate sample sizes (upto 2,300 cases and controls in
the discovery phase). In other human diseases it is accepted that
international collaboration is necessary to reach the required
sample sizes. Examples of such large undertakings are the DIAGRAM
consortium15 (diabetes, >45,000 individuals), CARDIOGRAM/C4D
consortium16,17 (65,000 coronary artery disease cases and 130,000
controls) and the largest up to now: the GIANT-consortium which
examines anthropometric traits in >250,000 individuals18. Within
OA, there are several initiatives to collaborate in order to reach the
sample sizes that are required to ﬁnd new robust GWAS signals. The
results of the largest collaborative effort up to now, the Arthritis
Research UK (ARC)-sponsored effort arcOGEN in the UK collabo-
rating with the European Union (EU)-sponsored TREAT-OA consor-
tium, were presented at the OARSI-meeting in 2011 and 2012 and
are about to be published at the time of writing19. With more than
7,000 OA cases in the discovery, they identiﬁed nine newgenetic loci
to be involved in OA. The large arcOGEN study shows that bigger
sample sizes do result in larger number of genetic loci identiﬁed,
and therefore it is anticipated that even larger collaborative efforts
within the OA genetics ﬁeld will result in more genes and novel
pathways involved in OA, and consequently also a better under-
standing of the disease mechanism. During the last 9 months,
several cohort studies have acquired new GWAS-data, including the
OA Initiative, the Johnston County study, the Study of Osteoporotic
Fractures and MrOs studies. These deeply phenotyped cohorts will
certainly help genetics of OA forward.
Phenotypes in OA
Figure 2 shows the number of identiﬁed genetic susceptibility
loci (based on assessing only the common variants through GWAS)
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Fig. 2. Power of genetic studies depends on sample size and phenotype. The number of GWAS “hits” (SNPs with p < 5  108) as a function of sample size of the discovery cohort for
several major complex diseases including OA.
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several dichotomous disease outcomes, including OA. It shows that
there are large differences in number of identiﬁed loci between the
different phenotypes, with Crohns’ disease being a relatively easy
trait where dozens of loci were found with relatively low sample
size, while in Alzheimers’ disease and OA only a modest number of
loci were identiﬁed despite modestly large sample size. These
differences in “genetic accessibility” could reﬂect the heterogeneity
of the phenotype under study, which is an important determinant
of power to identify robust association20. In contrast to many
disorders that can be considered as the extreme of a normal
distribution of a physiological parameter (such as osteoporosis is
for bone mineral density (BMD)), OA is different, since it is not the
extreme of a distribution of cartilage degradation. The diagnosis of
OA is based on a combination of parameters including both clinical
features (pain and stiffness) as well as a structural damage
composite score (the most widely used is the Kellgren & Lawrence
score, K&L score), which includes formation aspects of bone
(osteophyte formation) and assessment of cartilage degradation. In
general, it is suspected that OA is an extremely heterogeneous
phenotype with differently deﬁned disease status as an extra
source of phenotype heterogeneity21.Fig. 3. Relationship among major and minor phenotypes anOne might consider that for genetic studies, it can be worth-
while to examine so-called endophenotypes. Endophenotypes are
measurable intermediate phenotypes that are generally closer to
the action of the gene product than the disease status, and thus
exhibit higher genetic signal-to-noise ratios22. Endophenotypes
often provide much greater power to localize and identify disease-
related QTLs than does disease status alone23. Useful endopheno-
types in OA might be cartilage characteristics or joint shape among
others. An example of this approach is a GWAS on cartilage thick-
ness which was published by our group very recently, identifying
the DOT1-like, histone H3 methyltransferase (DOT1L) gene to be
involved in cartilage thickness, as measured by joint spacewidth on
a radiograph24.
On the other hand, the major clinical outcome, pain, can also be
considered as a disease phenotype on its own, with joint destruc-
tion as one of the risk factors for getting chronic joint pain (see also
Fig. 3). Over the last year several papers were published that sug-
gested involvement of several genes involved in OA-related pain.
One study identiﬁed via a genome-wide linkage analysis in mice,
the P2X7 receptor gene to be involved in nerve-injury-induced pain
behavior25. Subsequently, in the same study, a missense variant in
the P2RX7 was found to be associated with post-mastectomy paind sub-phenotypes to be distinguished in OA research.
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ciation between variants in the gene that encodes PACE4, the
proprotein convertase subtilisin/kexin type 6 (PCSK6) gene and OA-
related pain26. Although both reported genetic associations need
further replication, these studies indicate that pain can, and maybe
should, be studied as a separate trait.
Biological mechanism behind genetic associations
The exact pathophysiological mechanisms are largely unknown
for the majority of the risk alleles of the polymorphisms identiﬁed
via GWAS screening in OA. One of the problems is the identiﬁcation
of the culprit gene, among the several genes that lie within a GWAS
hit region. Other problems can be the identiﬁcation of the causative
single nucleotide polymorphism (SNP) (among the many linked
SNPs in such an area), and subsequently the unraveling of what the
risk allele of the SNP actually does. For few genetic loci the func-
tional risk allele has been elucidated. For example, the GDF5 SNP
was shown to exert its effect via regulation of transcription of the
gene in which the risk allele led to lower expression levels27. Also
SNPs near the DIO2 (deiodinase, iodothyronine, type II) gene were
shown to affect transcription28. Both DIO2 and GDF5 are thought to
play a role in skeletal development. In addition, the recently
identiﬁed DOT1L gene was suggested to play a role in chondrogenic
bone development via regulation of Wnt-signaling24. In contrast, it
has been difﬁcult to identify the underlying biological mechanism
of one of the most robust genetic signals in OA: the Chr7q22 locus.
This locus harbors six genes with no obvious candidate gene to
pursue. Although there is some indication that GPR22 (G-protein
coupled receptor) might be the causal gene, evidence is not
conclusive29, and also other genes are now being implicated30,31.
Research is ongoing to elucidate the exact mechanism. For the nine
newly identiﬁed loci from the arcoGEN study, some of them are
intuitively easy to interpret, such as the CHST11 (carbohydrate
(chondroitin 4) sulfotransferase 11) (involved in formation of chon-
droitin and dermatan sulfate, important components of cartilage
proteoglycans) and FTO (fat mass and obesity associated) (increasing
risk for knee OA by inﬂuencing BMI), but others need much
more work.
Next steps in OA genomic research
Genomic research in OA has progressed signiﬁcantly over the
last years. However, the resulting novel ﬁndings have not been
accompanied by clinically applicable tools for risk prediction,
diagnosis or therapeutic interventions. Novel methods and
approaches are emerging that follow the recent genetic ﬁndings for
OA. There are a few key areas that will be critical for successful
translation of the genomic ﬁndings to the clinic. First, Next
Generation Sequencing (NGS) will identify rare and novel variants
associated with OA or its endophenotypes, beyond the ones that
were captured by current GWAS techniques. Since GWAS assesses
only 0.1% of the nucleotides in the human genome much progress
can be expected from application of NGS (that assesses virtually all
nucleotides) although the approach has yet to mature in terms of
study designs and interpretation of data. Second, technological
advances will also put forward the ﬁelds of transcriptomics and
epigenetics as possible tools to improve understanding of the
pathophysiology of OA and clinical translation.
NGS
Sequencing technology has now advanced to a stage where it is
possible to generate a complete catalog of all variants present
within a given DNA sequence rather than having to rely on markersand patterns of linkage disequilibrium. NGS platforms have mark-
edly decreased the cost of DNA sequencing when compared with
Sanger sequencing. Hybridization approaches in NGS have enabled
selection of the portion of the genome that is protein coding
(roughly 1% of the genome), the so-called “exome”. Sequencing just
the exome (rather than the entire genome) is more cost-effective
and targets the part of the genome that is most likely to directly
affect the translated proteins. Hence biological interpretation is
relatively straightforward.
Over the past year, whole-exome sequencing has been
successfully utilized to identify new genes for several Mendelian
diseases that were not yet elucidated with the classical linkage
approach32. Most studies have sequenced the exomes of one or
a few individuals affected with the disorder. Variants seen in these
individuals are typically compared with those from reference
individuals (unaffected individuals who are family members or
unrelated). Variants that are shared by affected individuals and are
not present in the unaffected population are considered causal
candidates. Important to note is that over 3,000 novel mutations
are identiﬁed in each individual (irrespective of case/control
status), and so ﬁltering out the mutations that are not causative via
family-information is essential in this approach. It is anticipated
that this strategy will also identify new mutations in unresolved
Mendelian syndromic forms of early onset OA.
What about exome or whole-genome sequencing to identify
rare variants that confer a large effect on common, complex form of
OA? The optimal study design for complex traits will depend on the
frequency of the genetic variant(s) that are the source of the
association signal. However, without the extra information of
a familial design, sequencing in the open population will meet its
statistical boundaries. Statistical analysis needs to account for type I
error in the huge datasets that are produced, since preliminary
analysis of the ﬁrst population-based NGS exome-datasets show
over 300,000 new low-frequent mutations in 500 individuals.
Consequently, there is also a need to develop methods that can
distinguish phenotype-relevant variants from commonly shared
alleles. Therefore, NGS has up to now mainly been applied to
so-called extreme phenotypes, representing the extremes of a
phenotype distribution in the hope to increase the likelihood of
ﬁnding rare variants associatedwith the disease phenotype. For OA,
such an extreme phenotype could be comparing young persons
with OA at multiple sites against old persons without OA. There
are also efforts ongoing to completely sequence large cohorts
that have OA data. This will undoubtedly result in novel ﬁndings in
the OA ﬁeld, such as an enormous amount of new DNA-variants,
including SNPs and structural variants, small and large insertions/
deletions. Yet, replication strategies and the required power are
now being debated given that the rare variants themselves might
not so much be the “replicable unit” rather than the affected gene.
Coupling all these genetic variants to function (through tran-
scriptomics and epigenetics) is one of the major tasks of genomic
research over the next decade.
Epigenetics
Epigenetics investigates the mechanisms of the control of
gene expression that is apart from genetic variants. The most
investigated epigenetic modiﬁcation is DNA methylation but
also histone modiﬁcations and miRNAs are epigenetic phenomena
that are under investigation. Epigenetics might be crucial for
understanding the molecular basis of complex diseases such as
OA33. Although epigenetic modiﬁcations can be genetically deter-
mined, for example by genetic variants in CpG sites and hence can
result in differential methylation, they can also be modiﬁed by
environmental inﬂuences, such as diet34. DNA methylation can be
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applied successfully for GDF5, where it was demonstrated that the
genetic effect of the rs143383 SNP on GDF5 expression is modu-
lated epigenetically by DNA methylation35. In addition, similar
approaches were presented for DIO2 at the OARSI, also indicating
that this gene is under control of both genetic as well as epigenetic
differences28,36.
DNA methylation can now be studied on a genome-wide scale
by methylation arrays for which the latest arrays contain 450,000
CpG sites. The ﬁrst studies are appearing now that identify differ-
ential methylation signatures for disease states. A ﬁrst pilot study
examining 27,000 CpG sites in OA cartilage specimens was pre-
sented at the OARSI-meeting by Fernandez-Tajes et al. They showed
suggestive evidence for different subtypes of OA based on clus-
tering of the methylation proﬁles37.
Transcriptomics
Similar to epigenetic marks, gene expression is determined by
both genetic and environmental inﬂuences. The transcriptome is
highly dynamic and therefore gene-expression analysis at a single
time point reﬂects a snapshot of the cellular/tissue condition, but
does not necessarily reﬂect biological variation over time. In
contrast to the very stable DNA molecules, RNA is instable and
therefore sample preparation is more difﬁcult and crucial.
RNA-expression analysis can be used to examine whether the
identiﬁed genetic association is explained by regulating RNA-levels
of a nearby gene by simultaneously determining RNA-expression
levels and genetic variation (see also Fig. 4). This has been done on
a genome-wide scale, to identify so-called expression QTL (eQTL)
analysis for peripheral blood and other tissues, such as liver and
brain. In bone and joint tissues such a genome-wide eQTL analysis
has not been established yet. However, for some recently identiﬁed
OA genes, such as GDF5, DIO2, and dihydrouridine synthase 4-like
(DUS4L), HMG-box transcription factor 1 (HBP1), component of
oligomeric golgi complex 5 (COG5) (the last three genes are part of
the Chr7 cluster) allele speciﬁc expression in joint tissues showed
that indeed these genes were differentially expressed between the
different genotype groups of the genetic variants27,28,30.
Several studies have analyzed (independent of genotype)
genome-wide gene-expression microarray data in human end-
stage OA cartilage collected at the time of joint replacement.
These studies generally lack large numbers and independent
replication of the ﬁndings and so replication of such ﬁndings is also
highly recommended before interpretation and validity can be
properly assessed. Expression signatures can also be used as
biomarkers for disease. This is actively done in the clinical practice
of oncology, but not for OA up to now. Of course, the target tissues
of the joint cannot be sampled for biomarker use in early disease,
and therefore use of transcriptomics as biomarkers should beEnvironment RNA
DNAEpigenetic
modification
OA (endo)-
Phenotype
Expression QTL Diff. Expression
Clinical QTL
Fig. 4. Ongoing efforts in genetics and genomics to disentangle the functional genome
and elucidate the molecular mechanisms underlying OA.limited to easily obtainable tissues, such as blood. An interesting
ﬁrst study of Attur et al. showed an association between circulating
Interleukine 1 (IL-1)beta expression levels and progression of knee
OA38, which supports the idea of low grade systemic inﬂammation
being present in OA. This ﬁnding, of course needs further large scale
replication and validation, before it can considered for imple-
mentation in the clinical practice.
New technological advances are also entering the tran-
scriptomics research ﬁeld. With the advent of NGS technologies,
RNA sequencing (RNA-seq) by NGS has emerged as a powerful tool
for transcriptome analysis.
It is likely that the microarray-based gene-expression proﬁling
technology will be replaced by RNA-seq based expression proﬁling,
because RNA-seq will make it possible to explore much more
variation of the transcriptome compared to array-technology.
Besides the much wider dynamic range of signal, RNA-seq has
the ability to comprehensively detect novel transcripts and mRNA
variants resulting from alternative promoter usages, splicing, pol-
yadenylation and sequence variation; and lowered background.
At the OARSI-meeting in Barcelona, a ﬁrst study using this RNA-
seq method was presented which highlighted some new genes
upregulated in OA cartilage compared to controls39. It is clear that
these new approaches render an enormous amount of data, and
new methods to analyze these rich data are needed and being
developed.Summary
Technological advances in analyzing the major biomolecules
DNA and RNA, together with better statistical modeling and
improved computational capacity and software have transformed
the genomics ﬁeld rapidly over the last years. Genetic research in
particular has received an enormous boost when GWAS was
introduced as a technique to identify genes in complex traits. For
OA, GWAS is now becoming more successful in identifying new OA
genes. More power in genetic analysis, reached via a combination of
increasing sample size and reﬁnement of the OA-phenotypes will
continue this success. The next technological step is coming with
NGS, making it possible to fully sequence many genomes at the
basepair level. Developing in parallel are a number of new
approaches at different levels: epigenomics, transcriptomics, and
maybe also proteomics and metabolomics (although not reviewed
here). These new genome-wide approaches can offer us new
insights in genome function. Studying the DNA sequence with
GWAS and NGS at the population level will result in a nearly
complete picture of genetic variation in the static DNA-backbone in
relation to the many phenotypes and clinical states we can distin-
guish in OA. An important next step is to add dynamic data of
epigenomics and transcriptomics. Integrating these areas is
necessary to fully understand a complex disease, like OA. The next
few years will yield more insights into the relationship between
genotype and OA-phenotypes, and hopefully identify dominant
gene networks and pathways in patient subsets of OA. This would
then open up new avenues for targeted therapy.Author contributions
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